ReviewCureus2026
Gut Microbiome Composition and Response to Immune Checkpoint Inhibitors in Melanoma: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors have significantly improved clinical outcomes in patients with advanced melanoma; however, treatment response remains highly variable, and reliable predictive biomarkers are lacking. Emerging evidence suggests that the gut microbiome influences host immune regulation and may contribute to this variability. This systematic review evaluated the association between gut microbiome composition and response to immune checkpoint inhibitors in melanoma, with a focus on potential biological mechanisms, predictive biomarkers, and therapeutic implications. A systematic search of the PubMed database was conducted to identify studies published between 2015 and 2025. Eligible studies included original observational investigations and secondary analyses of melanoma microbiome datasets that examined associations between gut microbiome characteristics and response to immune checkpoint inhibitors. Interventional fecal microbiota transplantation studies, dietary or probiotic intervention trials, exposure-only studies (including antibiotic, proton pump inhibitor, or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.